# QT interval prolongation and mortality in sepsis: a retrospective cohort study from the MIMIC-IV database

**Authors:** Jin-you Zhang, Yang Chen, Ying-xi Zhang, Bao-jun Yang

PMC · DOI: 10.1186/s12872-026-05519-z · 2026-01-16

## TL;DR

QT interval prolongation is linked to higher mortality in sepsis patients, according to a study using ICU data.

## Contribution

This study is the first to examine the long-term mortality risk of QT prolongation in sepsis patients using the MIMIC-IV database.

## Key findings

- Patients with QT prolongation had significantly higher 28-day and 1-year mortality rates.
- Propensity score matching confirmed the increased mortality risk in the QT prolongation group.
- The study found a 34% increased risk of 28-day mortality and 40% increased risk of 1-year mortality in QT prolongation patients.

## Abstract

Sepsis is a leading cause of mortality in patients admitted to the intensive care unit (ICU), and QT prolongation (QTP) is common in critically ill patients. However, the association between QTP and long-term mortality in sepsis remains unexamined.

This retrospective study included patients meeting the Sepsis-3 criteria upon ICU admission between 2008 and 2019, identified from the Intensive Care Medical Information Mart IV (MIMIC-IV) database. Patients were categorized into two groups based on the presence (QTP group) or absence (non-QTP group) of QTP. Clinical outcomes were compared between patients with and without QTP. We used Kaplan–Meier analysis to compare the 28-day and 1-year all-cause mortality between septic patients with and without QTP. Furthermore, we utilized multivariate regression, propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and a survey-weighted generalized linear model to assess the association of QTP with 28-day and 1-year all-cause mortality in patients with sepsis.

A total of 4,845 patients were enrolled, with 1,424 (29.4%) in the QTP group. Compared with the non-QTP patients, the QTP group had significantly higher 28-day mortality (19.17% vs. 13.15%, p < 0.001) and 1-year mortality (33.99% vs. 24.82%, p < 0.001). Following PSM, the QTP group exhibited significantly higher mortality at both 28-day mortality (18.81% vs. 15.51%, p < 0.05) and 1-year mortality (33.60% vs. 27.64%, p < 0.001) compared to the non-QTP group. Patients in the QTP group exhibited increased risk of both 28-day mortality (adjusted OR = 1.34, 95% CI: 1.11–1.61, p = 0.002) and 1-year mortality (adjusted OR = 1.40, 95% CI: 1.20–1.63, p < 0.001).

The incidence of QTP was significantly elevated in ICU patients with sepsis compared with the general population and QTP was associated with increased risk-adjusted 28-day and 1-year mortality in ICU patients with sepsis.

The online version contains supplementary material available at 10.1186/s12872-026-05519-z.

## Full-text entities

- **Genes:** IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, KCNJ2 (potassium inwardly rectifying channel subfamily J member 2) [NCBI Gene 3759] {aka ATFB9, HHBIRK1, HHIRK1, IRK1, KIR2.1, LQT7}
- **Diseases:** chronic kidney disease (MESH:D051436), SQL (MESH:D011778), CCI (MESH:C566784), end-stage renal disease (MESH:D007676), CAD (MESH:D003324), LQTS (MESH:D008133), inflammation (MESH:D007249), bundle branch block (MESH:D002037), arrhythmia (MESH:D001145), myocardial injury (MESH:D009202), kidney disease (MESH:D007674), sudden cardiac death (MESH:D016757), septic (MESH:D001170), Hypokalemia (MESH:D007008), Atrial fibrillation (MESH:D001281), Comorbidity (MESH:D004194), immune dysfunction (MESH:D007154), acute kidney and liver injuries (MESH:D017114), COPD (MESH:D029424), liver disease (MESH:D008107), HF (MESH:D006333), death (MESH:D003643), coagulopathy (MESH:D001778), Organ Failure (MESH:D009102), arrhythmic (OMIM:212500), Sepsis (MESH:D018805), MIMIC-IV (MESH:D006011), end-stage liver disease (MESH:D058625), Torsade de Pointes VT (MESH:D016171), VT (MESH:D017180), Critically ill (MESH:D016638), SIRS (MESH:D018746), stroke (MESH:D020521), infection (MESH:D007239), VF (MESH:D014693), interval (OMIM:610141), hypocalcemia (MESH:D006996), systemic (MESH:D015619), hypomagnesemia (OMIM:613882)
- **Chemicals:** carbon dioxide (MESH:D002245), chloride (MESH:D002712), potassium (MESH:D011188), oxygen (MESH:D010100), PCO2 (-), creatinine (MESH:D003404), sodium (MESH:D012964), bicarbonate (MESH:D001639), lactate (MESH:D019344), urea nitrogen (MESH:C530477), PO2 (MESH:C093415), fluoroquinolone (MESH:D024841), salt (MESH:D012492), macrolide (MESH:D018942), magnesium (MESH:D008274)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12825248/full.md

---
Source: https://tomesphere.com/paper/PMC12825248